Treatment Outcome Following Transarterial Chemoembolization in Advanced Bone and Soft Tissue Sarcomas.

Abstract

Transarterial chemoembolization (TACE) is used to treat unresectable bone and soft tissue sarcoma (STS) and as a pre-surgical adjuvant treatment. However, its efficiency for advanced STS is undetermined. This study evaluated TACE's efficiency in treating advanced STS and prognostic factors for patient survival. We enrolled 39 patients with unresectable STS who underwent TACE as an alternative treatment during 2010-2014, with overall survival (OS) as the primary end point. Cancer pain was evaluated by visual analogue scores (VAS) before and after TACE procedures. Factors that affect survival were evaluated by multivariate analyses (Cox proportional hazard model). Mean OS after TACE was 23.7±2.1months, with 1-year OS 71.5%, 2-year OS 45.8%, and 3-year OS 32.5%. Lesion number and tumor stage were key predictors of survival. TACE was found to decrease cancer pain VAS and increase relapse interval. Size of polyvinyl alcohol (PVA) particle diameter (P=0.03) and imaging response (P=0.044) were also found to affect relapse interval. TACE was an effective treatment for advanced STS, with a 32.5% 3-year OS rate, and led to lower cancer pain VAS and longer relapse intervals than chemoinfusion only. Smaller PVA particles are preferable during the TACE procedure.